Prothena (PRTA) Competitors

Prothena (NASDAQ:PRTA) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Do institutionals and insiders believe in PRTA or DYN?

97.1% of Prothena shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 9.2% of Prothena shares are held by company insiders. Comparatively, 14.1% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media refer more to PRTA or DYN?

In the previous week, Dyne Therapeutics had 4 more articles in the media than Prothena. MarketBeat recorded 5 mentions for Dyne Therapeutics and 1 mentions for Prothena. Dyne Therapeutics' average media sentiment score of 0.90 beat Prothena's score of 0.56 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better valuation & earnings, PRTA or DYN?

Prothena has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$10.34M	45.65	-$122.31M	-$5.64	-1.55
Dyne Therapeutics	N/A	N/A	-$317.42M	-$3.86	-3.26

Do analysts rate PRTA or DYN?

Prothena presently has a consensus price target of $30.25, indicating a potential upside of 244.93%. Dyne Therapeutics has a consensus price target of $33.80, indicating a potential upside of 168.68%. Given Prothena's higher probable upside, research analysts clearly believe Prothena is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Dyne Therapeutics	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Which has more volatility and risk, PRTA or DYN?

Prothena has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Is PRTA or DYN more profitable?

Dyne Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -2,929.30%. Prothena's return on equity of -62.17% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-2,929.30%	-62.17%	-54.43%
Dyne Therapeutics	N/A	-64.12%	-56.75%

Summary

Dyne Therapeutics beats Prothena on 9 of the 16 factors compared between the two stocks.